NICM
ARRY

Neo Ivy Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Neo Ivy Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-35,381
Closed -$862K – 454
2019
Q1 		$862K Buy
+35,381
New +$737K 0.49% 91

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Neo Ivy Capital Management's ARRY Position: Q2 2019 in Review

Neo Ivy Capital Management sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 35,381 shares — an estimated $862K sold.

Neo Ivy Capital Management first reported a position in ARRY in Q1 2019 and held it in 1 quarter. The position peaked at $862K in Q1 2019. 319 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Neo Ivy Capital Management reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Neo Ivy Capital Management sold 35,381 Array Biopharma Inc shares in Q2 2019, an estimated $862K.
  • Neo Ivy Capital Management first reported a position in Array Biopharma Inc in Q1 2019 and held it in 1 quarter.
  • Neo Ivy Capital Management's Array Biopharma Inc position peaked at $862K in Q1 2019.
  • 319 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Neo Ivy Capital Management's 13F filing for Q2 2019, filed 15 Aug 2019.